FIELD: chemistry.
SUBSTANCE: invention relates to new compounds of formula (I) and pharmaceutically acceptable salts of the said compound, which has c-met kinase inhibitory properties. In general formula (I) 
W is -N=, and X is hydrogen, Y is hydrogen or A2-R group; A2 is C1-C5alkylene; R is hydroxy; n equals 1, and Z is benzyloxy; or alternatively W is -CH=, and X is hydrogen, OR1; R1 is chosen from A1-Q1group; A1 is 1,2-ethylene or 1,3-propylene group; Q1 is hydroxyl; Y is a A2-R group; A2 is C1-C5alkylene; R is hydroxy; n equals 1, and Z is C1-C3alkoxy, substituted with pyridinyl, and pharmaceutically acceptable salts of the said compound.
EFFECT: can be used for treating cancer and cancer-related diseases.
8 cl, 36 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 2-(2,6-DICHLOROPHENYL)DIARYLIMIDAZOLES, METHOD FOR THEIR PREPARING (VARIANTS), INTERMEDIATES COMPOUNDS AND PHARMACEUTICAL COMPOSITION | 2003 |
|
RU2320645C2 |
| SUBSTITUTED PYRAZOLES, PHARMACEUTICAL COMPOSITION BASED ON SAID, METHOD OF PATIENT TREATMENT, INTERMEDIATE COMPOUND | 1993 |
|
RU2130453C1 |
| NAPHTYLENE DERIVATIVE AS CYTOCHROME P450 INHIBITORS | 2004 |
|
RU2363696C2 |
| NEW COMPOUNDS AS MODULATOR OF OPIOTIC RECEPTORS | 2003 |
|
RU2332411C2 |
| DERIVATIVES OF HYDROXYMETHYLFURAZAN CARBOXYLIC ACID AND PHARMACEUTICAL PREPARATION | 1994 |
|
RU2134687C1 |
| SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2815814C1 |
| USE OF EP4 RECEPTOR ANTAGONIST IN TREATMENT OF CARTILAGE DISEASE | 2014 |
|
RU2663620C2 |
| BISPHENOL DERIVATIVES AND THEIR USE AS ACTIVITY MODULATORS OF ANDROGEN RECEPTOR | 2017 |
|
RU2767257C2 |
| FGFR INHIBITOR AND ITS APPLICATION | 2018 |
|
RU2745035C1 |
| ASYMMETRIC ARYLPHOSPHITES, POLYMERIC COMPOSITION AND ITS PREPARING | 1992 |
|
RU2071478C1 |
